The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A propensity-score matched analysis for time to trabectedin-failure in advanced myxoid liposarcoma patients.
 
Giovanna Roberta Sanfilippo
Consulting or Advisory Role - Boehringer Ingelheim; RAIN (Inst)
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); AORG Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi-Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); RAIN (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Silva Ljevar
No Relationships to Disclose
 
Andrea Franza
No Relationships to Disclose
 
Chiara Fabbroni
No Relationships to Disclose
 
Carlo Morosi
No Relationships to Disclose
 
Angelo Dei Tos
No Relationships to Disclose
 
Alessandro Gronchi
No Relationships to Disclose
 
Dario Callegaro
Consulting or Advisory Role - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - 'FIRMA PROGNOSTICA PER SOGGETTI AFFETTI DA SARCOMI RETROPERITONEALI' Italian patent number 102024000004447 from Feb 29th, 2024. This is a prognostic transcriptomic signature for patients with retroperitoneal sarcoma.
 
Rosalba Miceli
Honoraria - Boehringer Ingelheim
 
Paolo Casali
No Relationships to Disclose